Compare Adaptive Biotechnologies Corp (ADPT) vs US Global Jets ETF (JETS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs US Global Jets ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while US Global Jets ETF trades at $31.52. Which is the better fit depends on your goals.
| ADPT | JETS | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $33.34 |
52-Week Low | $10.24 | $23.12 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
JETS trades at $33.34, up 0.42% with a bullish technical outlook from moving averages but overbought RSI signals. The ETF faces headwinds from soaring airline fuel costs, which jumped 85% in May to $6.7 billion (Reuters, 2026-07-07), pressuring profitability across the sector. Recent news highlights industry challenges including engine maker delays and fare pressures, though falling oil prices offer some relief.
Outlook remains cautious due to cyclical risks and fuel volatility; the ETF provides diversified airline exposure but requires monitoring of margin compression. Investment opportunity hinges on oil price trends and travel demand recovery, with significant downside risk if cost pressures persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →
